Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Galapagos NV    GLPG

GALAPAGOS NV

(GLPG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
103.02(c) 102.55(c) 100.51(c) 101.72(c) 100.01(c) Last
208 145 131 335 163 690 132 528 371 804 Volume
-0.40% -0.46% -1.99% +1.20% -1.68% Change
More quotes
Financials
Sales 2020 501 M 605 M 605 M
Net income 2020 -322 M -388 M -388 M
Net cash position 2020 3 913 M 4 725 M 4 725 M
P/E ratio 2020 -19,2x
Yield 2020 -
Sales 2021 503 M 608 M 608 M
Net income 2021 -379 M -458 M -458 M
Net cash position 2021 3 494 M 4 219 M 4 219 M
P/E ratio 2021 -18,8x
Yield 2021 -
Capitalization 5 391 M 6 518 M 6 510 M
EV / Sales 2020 2,95x
EV / Sales 2021 3,77x
Nbr of Employees 1 407
Free-Float 73,8%
More Financials
Company
Galapagos NV specializes in the research and development of drugs based on novel targets discovered and validated in human primary cells. Net sales break down by activity as follows: - discovery and development of drugs (98.8%); - other (1.2%). Net sales are distributed geographically as follows: Europe (5.8%) and North America (94.2%). 
Sector
Biotechnology & Medical Research
Calendar
01/14 | 09:10amPresentation
More about the company
Notations Surperformance© of Galapagos NV
Trading Rating : Investor Rating :
More Ratings
All news about GALAPAGOS NV
01/12GALAPAGOS NV : - Gilead holds 25.54% of Galapagos shares
AQ
01/11Gilead holds 25.54% of Galapagos shares
GL
01/06GALAPAGOS : to present at 39th Annual J.P. Morgan Healthcare Conference
AQ
01/04Selvita completes acquisition of Fidelta from Galapagos
GL
2020Galapagos Shares Drop 19% After Gilead Won't Seek FDA Approval for Jyseleca
DJ
2020GILEAD SCIENCES : and Galapagos Announce New Commercialization and Development A..
AQ
2020GLOBAL MARKETS LIVE : Moderna, Google, Twitter….
2020Gilead, Galapagos Amend Arrangement on Jyseleca; Gilead Won't Pursue FDA Appr..
DJ
2020Upbeat business activity, vaccine hopes lift European shares
RE
2020GALAPAGOS : Gilead Abandon US FDA Application for Arthritis Treatment
MT
2020GILEAD SCIENCES : says not to pursue U.S. approval for rheumatoid arthritis drug
RE
2020GILEAD SCIENCES : abandons filgotinib for rheumatoid arthritis in U.S.
RE
2020GALAPAGOS : Gilead and Galapagos Announce New Commercialization and Development ..
BU
2020Gilead  and  Galapagos  announce  New  Commercialization  and  Development  A..
GL
2020SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
More news
News in other languages on GALAPAGOS NV
01/07AVIS D'ANALYSTES DU JOUR : Amadeus, Aston Martin, Atos, EDF, Galapagos, Inficon,..
2020AVIS D'ANALYSTES DU JOUR : ABB, Delta Plus, EDP, Galapagos, HelloFresh, Sika, Ve..
2020AVIS D'ANALYSTES DU JOUR : ArcelorMittal, ASML, BioMérieux, Flatex, HelloFresh, ..
2020EN DIRECT DES MARCHES : Atos, Crédit Agricole, Eramet, Valneva, Nanobiotix, Goog..
2020AVIS D'ANALYSTES DU JOUR : Amadeus, Cellnex, Eurazeo, Givaudan, Kering, Klépierr..
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 94,40 €
Last Close Price 82,42 €
Spread / Highest target 51,7%
Spread / Average Target 14,5%
Spread / Lowest Target -10,2%
EPS Revisions
Managers and Directors
NameTitle
Onno van de Stolpe Chief Executive Officer & Executive Director
Raj B. Parekh Chairman
Bart Filius Chief Operating & Financial Officer
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALAPAGOS NV1.04%6 518
MODERNA, INC.24.10%51 332
LONZA GROUP AG3.31%49 176
CELLTRION, INC.-8.36%43 849
IQVIA HOLDINGS INC.4.81%36 066
SEAGEN INC.6.06%31 812